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Summary Historically, archaeological evidence, post-mortem findings and retro-
spective analysis of leprosy institutions’ data demonstrates a high observed incidence
of concomitant infection with leprosy and tuberculosis (TB). However, reports of
concomitant infection in the modern literature remain scarce, with estimates of
annual new case detection rates of concomitant infection at approximately 0·02
cases per 100,000 population. Whilst the mechanism for this apparent decline in
concomitant infections remains unclear, further research on this topic has remained
relatively neglected. Modelling of the interaction of the two organisms has suggested
that the apparent decline in observations of concomitant infection may be due to the
protective effects of cross immunity, whilst more recently others have questioned
whether it is a more harmful relationship, predisposing towards increased host
mortality. We review recent evidence, comparing it to previously held understanding
on the epidemiological relationship and our own experience of concomitant infection.
From this discussion, we highlight several under-investigated areas, which may
lead to improvements in the future delivery of leprosy management and services, as
well as enhance understanding in other fields of infection management. These
include, a) highlighting the need for greater understanding of host immunogenetics
involved in concomitant infection, b) whether prolonged courses of high dose steroids
pre-dispose to TB infection? and, c) whether there is a risk of rifampicin resistance
developing in leprosy patients treated in the face of undiagnosed TB and other
infections? Longitudinal work is still required to characterise these temporal
relationships further and add to the current paucity of literature on this subject matter.
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Introduction
Tuberculosis (TB) and leprosy are two ancient pathogens, which have been identified as
infecting humans 90001 and 40002 years ago, respectively. It has been shown from
archaeological evidence, post-mortem findings and retrospective analysis of leprosy
institutions’ data that there is a highly observed incidence of concomitant infection with
leprosy and TB.3–6 However, reports of concomitant infection in modern literature remain
scarce.7–18 Estimation of the annual new case detection rate (ANCDR) in India, where both
TB (ANCDR 181 per 100,000 in 201119) and leprosy (ANCDR 10·35 per 100·000 in 201120)
remain endemic, suggest that you would only detect 0·019 cases of concomitant infection per
100,000 population. Whilst some have questioned whether this apparent decline in
observation is a harmful consequence of concomitant infection,21 others have suggested that
it is the protective effects of cross immunity from infection with one of these organisms.22
Many experts in the field also feel that there may be no interaction between these closely
related organisms and that these observations are simply coincidental, coexistence.
The interaction between TB and leprosy has been relatively neglected in the literature in
the modern era. With the development of new evidence surrounding the epidemiological
interaction between organisms21 we aimed to identify current cases of concomitant infection
described in the literature and review current evidence in support of each epidemiological
theory. We also reviewed our own experience of concomitant infection and based on these
experiences raise several questions which future investigation may provide benefit to the
delivery of leprosy management, reduce the risk of concomitant infection and also add to
other areas of infectious disease management. The latter of which, will become increasingly
significant as augmentation of services with other specialist fields continues to increase.
WHAT CASES OF CONCOMITANT INFECTION ARE REPORTED IN
THE LITERATURE?
In 1982, Kumar et al. observed that TB appeared to occur across the entire spectrum of leprosy.7
This is supported by case reports in the literature describing cases of TB in: tuberculoid,11–13
borderline,13–16 and lepromatous8,13,15,17,18 leprosy patients. The time gap from onset/detection
of both infections varied in reports from2months17 to 15 years.13Whilemost report that leprosy
precedes TB, Agawal et al.,17 Agnihotri et al.,12 and Trindade et al.10 report cases of TB
preceding. Both type-I10,14 and type-II15,16 lepra reactions have also been reported.
On review of data from three leprosy referral centres in Hyderabad, India from 2000 to
2013, we have identified 3 cases of concomitant disease (Table 1). Two were sputum positive,
pulmonary TB cases associated with lepromatous leprosy. One case was extra-pulmonary,
CNS TB, confirmed with real time polymerase chain reaction (RT-PRC) of cerebrospinal
fluid associated with lepromatous leprosy. All cases of leprosy had been confirmed by slit
skin smear.
WHAT IS THE EPIDEMIOLOGICAL SIGNIFICANCE OF TB AND
LEPROSY CO-INFECTION?
It was Fernandez, in 1939, who first proposed the suggestion that Bacillus Calmette-Guerin
(BCG) vaccination may confer protection against leprosy. His observation that a large
number of lepromin-negative children became positive for the protein following BCG
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vaccination led him to hypothesise that this may confer some protection against the disease.23
More recently, several large, high level evidence studies have supported Fernandez’s original
observations from 75 years ago.24–28 For example, Goulart et al.measured the relative risk of
leprosy occurrence in household contacts (n ¼ 1,396) in Brazil, an endemic region for the
disease, over a 5 year period. Their results showed that having a BCG scar conferred a 98%
(RR ¼ 0·02) protection against MB leprosy forms compared to not having a BCG scar.24
In 2007, Zodpey reported a meta-analysis in which they analysed 29 case-control, cohort and
randomized control studies investigating the effectiveness of BCG vaccination in the
prevention of leprosy.29 The findings of this study strongly support the protective effect of
BCG vaccine.29
The belief that there is a level of cross immunity provided to leprosy from exposure to
other myocbacterial species, such as TB, was first described by Chaussinand in 1948. He
observed that the prevalence of leprosy was inversely related to that of TB and proposed
that prior TB exposure protected the individual against leprosy.30 Lietman et al. further
investigated this theory of cross immunity by modelling the elimination of leprosy from
Western Europe.22 They argued that leprosy was endemic in Western Europe from the 11th to
13th centuries. However, it nearly disappeared during the TB endemic of the 17th and 18th
century.31,32 Through mathematical modelling, the authors are able to conclude that TB could
have played a key role in the elimination of leprosy from Western Europe providing that
the basic reproduction rate of leprosy was relatively low.22
On the other hand, the co-existence of the two mycobacteria has been demonstrated in
archaeological samples by Donoghue et al.3 who identified DNA from both pathogens in the
same samples from several sites around the world. These dated from the Roman period to the
13th century.3 From these observations, the authors suggest that both socio-economic
conditions and immune changes in multi-bacillary (MB) leprosy, led to an increased
mortality in TB, leading to historical decline in leprosy. For example, in 1993, Glaziou et al.
reported on leprosy and TB co-infected patients (n ¼ 275) from institutions in French
Polynesia between 1902 and 1930 (pre anti-microbial treatment). Overall mortality in this
cohort was found to be 21%. Interestingly, there was a much greater mortality in MB
compared to paucibacillary (PB) patients (13% vs. 4% P ¼ 0·003).6 In fact, Hansen reported
similar findings in Oslo in 1895, citing TB as the major cause of death in his leprosy
subjects.33
It is hypothesized that, reduced cell mediated immunity plays a role in reactivation of
latent TB or super-infection with TB in MB patients. Lepromatous leprosy patients have been
demonstrated to mount a lower TNF-a response and have reduced inducible signalling
molecules, such as chemokine ligand-2 (CCL-2).13,34 This may explain the increased
dissemination and growth of TB in MB disease. However, Trindade et al. recently
investigated the cell mediated responses of two patients who were diagnosed with borderline
leprosy (BL) and TB. They were unable to find any aberrant response of the IFN-g/IL-12/23
axis on immunological evaluation.10 As genetic susceptibility to mycobacterial disease is
commonly found in this signalling pathway35 this may warrant further longitudinal work to
add power to any results surrounding this hypothesis.
Despite evidence to support this co-infection hypothesis, evidence cited from historical
texts needs to be considered circumspectly because of the problems with diagnosis during
these periods. There is also an element of bias because patients in institutions would likely be
at a higher risk of developing TB and would also be on life-long treatment, as opposed to
modern curative regimes (multi-drug therapy [MDT]), which are now available.
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In 2013, Hohmann & Voss-Bo¨hme used mathematical modelling to investigate the
epidemiological outcomes of the co-infection hypothesis. Through this model, they showed
that the disappearance of leprosy in certain parametric regions could be explained by
co-infection. Their model is based upon the incidence of leprosy epidemics, which suggests
that the basic reproductive number of leprosy is greater than one. Therefore this means that
the historical decline of leprosy requires external influences upon it.21 The authors argue that
the Lietman et al. cross-immunity model, relies on the reproductive number of TB always
being greater than that of leprosy.22 Therefore, in severe leprosy endemics the cross-
immunity hypothesis could not be used to explain declines in leprosy following these periods.
However, in the co-infection hypothesis the increased severity of a leprosy endemic would
make patients more susceptible to TB infection, potentially allowing an explanation for the
elimination of leprosy in these regions.21
The authors caution the reader that cross–immunity and co–infection theories may not be
exclusive and that both mechanisms may, in fact, reinforce the actions of one another.21
However, in the co-infection hypothesis an immunological relationship is not assumed as
increased susceptibility towards TB infection may result from a general immune response or
social stressor. In the cross-immunity hypothesis an immunological relationship is critical.
Therefore, the co-infection hypothesis can also explain the inverse relationship between the two
organisms if cross-immunity is not sufficiently supported by immunological evidence in the
future.21 Further investigation of immunogenetic host factors which predispose to protection/
resistance to concomitant infection may provide further insight into future novel therapeutic
targets for susceptibility, prevention and treatment of infection with either organism.
DOES MULTI -DRUG THERAPY (MDT) POSE A RISK OF RIFAMPICIN RESISTANCE
DEVELOPING IN UNDIAGNOSED TB CO-INFECTION?
Rifampicin is a key component of anti-tuberculosis chemotherapy.36 It has been
demonstrated that in the treatment of TB, rifamycin containing regimes are superior to
those devoid of a rifamycin agent.37 It was Kumar et al. in 1982 who postulated their
concerns about avoiding monotherapy of undetected TB with rifampicin as a once monthly
dose in MDT for leprosy. They feared that this may promote the development of rifampicin
resistance of TB in concomitantly infected patients.7
In our reported case, TB was detected 9 months in to MBMDT treatment. Encouragingly,
despite worries of rifamycin resistance, secondary to rifampicin monotherapy in MDT where
TB is undetected,7,16 all patients at our centres were successfully treated for TB with
conventional category-I anti-TB chemotherapy. None of the cases have suffered relapses of
TB since completing category-I treatment. It would have been beneficial to have obtained
sputum sensitivities from these patients at the time of TB diagnosis to ensure sensitivity to
rifampicin still remained. This is something which we are now considering implementing in
all future cases, to allow monitoring for development of rifamycin resistance.
Despite these concerns, there currently are no reports of rifampicin resistance identified in
co-infected patients. However, longitudinal studies are lacking and more vigilant monitoring
of co-infected patients on diagnosis of TB for rifampicin resistance is required to be able to
investigate this further. Although this may be an unlikely consequence of monthly rifampicin
treatment in India, where our cases are based, it may be a greater concern in regions
where leprosy patients take daily rifampicin, such as in the USA. It is important that rifampicin
resistance is viewed in consideration of general anti-microbial resistance and not just in
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isolation to leprosy resistance.38 This view has also been echoed in the WHO regional director
of South-East Asia in her vision statement39 and raises the question of whether broader
resistance screening is required in all concomitant infections during the course of leprosy
treatment to further strengthen antimicrobial stewardship and prevention of resistance.
ARE STEROIDS A RISK FACTOR FOR THE DEVELOPMENT OF TB IN LEPROSY?
Although many risk factors for TB are known, including HIV infection, diabetes mellitus,
transplant patients on immunosuppression and birth and travel in the developing world,38 the
use of steroids and development of TB is controversial. Jick et al. report an increased risk of
TB in patients on steroids in their case-control study investigating the link in a rheumatology
cohort in the United Kingdom.40
Sreeramareddy et al.15 and Prasad et al.16 have reported on co-infected patients who had
been treated with steroids before diagnosis of TB. Agarwal et al. report the case of a renal
transplant patient who had been taking multiple immunosuppressant drugs, including
steroids, for several years.17 However, major trials of steroid treatment in routine MDT for
leprosy, such as the TRIPOD studies, have failed to identify development of TB in some
300 patients who were followed up for over 24 months.41,42 However, these studies only
treated patients with low doses of prednisolone (around 20mg). Dosing used in routine clinics
in India can often be greater than this and for longer periods of time. For example, two patients
identified with co-infection in our report (cases 1 & 2) had been commenced on oral
prednisolone at 40mg initially. In case 1, we identified the patient had been taking steroids for
a period of 9 months. There was no previous history of TB or infected contacts. However,
there is no evidence of any screening for latent TB prior to commencement of steroid &MDT
treatment, so a temporal relationship is difficult to establish.
One weakness in the argument for steroids increasing the risk of developing TB is that a
large number of leprosy patients (especially MB leprosy, who as discussed above may be
more predisposed to TB co-infection) go on to develop lepra reactions, which require steroid
treatment. Therefore, this means that there is a high rate of steroid prescribing in leprosy. For
example, in a recent retrospective analysis of clinical characteristics of MB leprosy patients
(n ¼ 730) 54% developed lepra reactions.43 One study reports that in a region of Africa with
an ANCDR of 7·1 per 100,000 population, there was a ‘steroids started rate’ in one year of
1·26 per 100,000 population. Steroid treatment was for a minimum of 16 weeks to treat
reactions per patient.44 With an estimated ANCDR for co-infection of 0·019 per 100,000
patients (in India) the incidence of patients started on steroids is approximately 66 times
greater than the estimated incidence of co-infection with both diseases. Despite this,
longitudinal work would be required to identify any temporal relationship between steroids
and TB development with active screening of patients before commencing treatment.
Conclusion
Despite the paucity of reports, infection with leprosy and tuberculosis does occur
concomitantly. There is now a growing body of evidence to support the interaction of these
two organisms historically to the point that we can begin to consider that TB may have been
involved in the pre-MDT era decline in leprosy across Western Europe. On review of cases in
the literature along with new epidemiological modelling of concomitant infection, further
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work to characterise immunogenetic host factors may provide insight into future novel
therapeutic targets for susceptibility, prevention and treatment of infection. We highlight how
a greater understanding of the risk of development of rifampicin resistance, not only in the
context of leprosy must be considered. Finally, work to further characterise whether there is
a true temporal relationship between prolonged course, high dose steroid therapy and TB,
as is associated with so many other immunosuppressive therapies is urgently required. The
addition of data on these topics may help to improve future leprosy service provision as
well as highlight the need to approach infection prevention and anti-microbial stewardship
from a more holistic point of view. This will become integral as the augmentation of service
provision between different specialist areas continues to increase over the coming years.
Acknowledgements
We would like to thank the patients presented in the cases for their permission to publish their
anonymised data and the staff at Lepra India: Health in Action for their support in production
of this project.
Conflicts of interest
We have no conflicts of interest to declare. No funding or grants were received for the
production of this project.
References
1 Hershkovitz I, Donoghue HD, Minnikin DE et al. Detection and molecular characterization of 9000-year-old
Mycobacterium tuberculosis from a neolithic settlement in the EasternMediterranean. PLoS ONE, 2008; 10: 3426.
2 Robbins G, Mushrif Tripathy V, Misra VN et al. Ancient skeletal evidence for leprosy in India (2000 B.C.). PLoS
ONE, 2009; 4: 5669.
3 Donoghue HD, Marcsik A, Mathesion C et al. Co-infection of Mycobacterium tuberculosis and Mycobacterium
leprae in human archaeological samples: a possible explanation for the historical decline of leprosy. ProcBiolSci,
2005; 272: 389–394.
4 Premnath M, Ramu G. The association of tuberculosis and leprosy. J Indian Med Assoc, 1976; 20: 143–145.
5 Gray HH, Huldah B. Tuberculosis and leprosy at United States Public Health Services Hospital, Carville,
Louisiana 1922–1950. Int J Lepr, 1952; 20: 467–478.
6 Glaziou P, Cartel JL, Moulia-Pelat JP et al. Tuberculosis in leprosy patients detected between 2901 and 1991 in
French Polynesia. Int. J. Lepr, 1993; 61: 199–204.
7 Kumar B, Kaur S, Kataria S, Roy SN. Concomitant occurrence of leprosy and tuberculosis – a clinical,
bacteriological and radiological evaluation. Lepr India, 1982; 54: 671–676.
8 Flanagan PM, McIlwain JC. Tuberculosis of the larynx in a lepromatous patient. J Laryngol Otol, 1993; 107:
846–847.
9 Inamadar AC, Sampagavi VV. Concomitant occurrence of leprosy, cutaneous tuberculosis and pulmonary
tuberculosis – a case report. Lepr Rev, 1994; 65: 282–284.
10 Trindade MAˆ, Miyamoto D, Benard G et al. Leprosy and tuberculosis coinfection: clinical and immunological
report of two cases and review of the literature. Am J Trop Med Hyg, 2013; 88: 236–240.
11 Gupta MC, Prasad M. Associated infection of pulmonary tuberculosis and leprosy. Indian J Med Sci, 1971; 25:
183–185.
12 Agnihotri MS, Rastogi S, Agarwal RC. Tuberculosis and Leprosy. Ind J Tub, 1973; 20: 136–137.
13 Nigam P, Dubey AL, Dayal SG et al. The association of leprosy and pulmonary tuberculosis. Lepr India, 1979; 51:
65–73.
14 Lee HN, Embi CS, Vigelan KM, White CR, jr. Concomitant pulmonary tuberculosis and leprosy. J Am Acad
Dermol, 2003; 49: 755–757.
15 Sreeramareddy CT, Menezes RG, Kishore PV. Concomitant age old infections of mankind – tuberculosis and
leprosy: a case report. J Med Case Reports, 2007; 1: 43.
T. M. Rawson et al.294
16 Prasad R, Kumar Verma S, Singh R, Hosmane G. Concomittent pulmonary tuberculosis and borderline leprosy
with type-II lepra reaction in single patient. Lung India, 2010; 27: 19–23.
17 Agarwal DK, Mehta AR, Sharma AP et al. Coinfection with leprosy and tuberculosis in a renal transplant
recipient. Nephrol dial transplant, 2000; 15: 1720–1721.
18 Srilakshmi MA, Amit H, Lal J et al. Concomitant infection with pulmonary tuberculosis and lepromatous leprosy.
J Assosc Physicians India, 2003; 51: 528–529.
19 World Health Organisation; Global Tuberculosis report 2012. http://www.who.int/tb/publications/global_report/
en/ (Accessed June 2013).
20 National Leprosy Eradication Programme. NLEP – progress report for the year 2011 – 2012. Central leprosy
division. nlep.nic.in/pdf/ProgressReport2011-12.pdf (accessed 15/09/2013).
21 Hohmann N, Voss-Bo¨hme A. The epidemiological consequences of leprosy-tuberculosis co-infection.
Mathematical Biosciences, 2013; 241: 225–237.
22 Lietman T, Porco T, Blower S. Leprosy and tuberculosis: The epidemiological consequences of cross immunity.
Am J Public health, 1997; 87: 1923.
23 Rees RJW. BCG vaccination in mycobacterial infections. Br. Med. Bull, 1969; 25: 183–188.
24 Goulart IMB, Bernardes Souza D, Marques CR et al. Risk and Protective Factors for Leprosy Development
Determined by Epidemiological Surveillance of Household Contacts. Clinical and Vaccine Immunology, 2008;
15: 101–105.
25 Karonga Prevention Trial Group. Randomised control trial of single BCG, or combined BCG and killed
Mycobacterium lepraevaccine for the prevention ofLeprosy and tuberculosis inMalawi.Lancet, 1996;348: 17–24.
26 Convit J, Smiths P G, Zuniga M et al. BCG vaccination protects against leprosy in Venezuela: a case-control
study. Int. J. Lepr. Other Mycobact Dis, 1993; 62: 185–191.
27 Muliyil J, Nelson KE, Diamond EL. Effect of BCG on the risk of leprosy in an endemic area: a case-control study.
Int J Lepr Other Mycobact Dis, 1991; 59: 229–236.
28 Setia MS, Steinmaus C, Ho CS, Rutherford GW. The role of BCG in prevention of leprosy: a meta-analysis.
Lancet Infect Dis, 2006; 6: 162–170.
29 Zodpey SP. Protective effect of bacillus Calmet Guerin (BCG) vaccine in the prevention of leprosy: a meta-
analysis. Ind J Dermatol Venerol Leprol, 2007; 73: 86–93.
30 Chaussinand R. Tuberculosis and leprosy, antagonist diseases. Prevention of leprosy by tuberculosis. Int. J Lepr,
1946; 16: 431–438.
31 Bates JH, SteadWW. The history of tuberculosis as a global epidemic.Med Clin North Am, 1993; 77: 1205–1218.
32 Hastings RC. Leprosy. Edinburgh, Scotland: Churchill Livingstone, 1994.
33 HansenGA&Looft C.Leprosy: in its clinical and pathological aspects. Bristol: JohnWright&Co.Reprinted 1973.
34 Hasan Z, Jamil B, Zaidi I et al. Elevated serum CCL2 concomitant with a reduced mycobacterium-induced
response leads to disease dissemination in leprosy. Scand J Immunol, 2006; 63: 241–247.
35 Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol,
2002; 20: 581–620.
36 World Health Organization. Operational guide for national tuberculosis control programmes on the introduction of
fixed dose combination drugs (2002). WHO/CDS/TB/2002. 308-WHO/EDM/PAR/2002.6. Geneva, Switzerland:
WHO, 2010. http://wh1libdoc.who.int/hq/2002/WHO CDS TB 2002.308.pdf (Accessed June 2013).
37 Onyebujoh PC, Ribeiro I, Whalen CC. Treatment options for HIV-associated tuberculosis. J Infect Dis, 2007;
(Suppl 1): S35–S45.
38 World Health Organization. Guidelines for global surveillance of drug resistance in leprosy. http://www.searo.
who.int/entity/global_leprosy_programme/publications/guide_surv_drug_res_2009.pdf?ua=1 (accessed 20/02/
2014)
39 Singh PK. Healthier WHO South-East Asia Region; responsive Regional office. http://www.searo.who.int/
mediacentre/features/2014/rd-singh-vision/en/ (accessed 20/02/2014).
40 Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors and the risk of
tuberculosis. Arthritis and Rheumatism Arthritis care and research, 2006; 55: 19–26.
41 Smith WC, Anderson AM, Withington SG et al. Steroid prophylaxis for prevention of nerve function impairment
in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ, 2004; 328(7454): 1459.
42 Richardus JG, Withington WH, Anderson AM et al. Adverse events of standardized regimens of corticosteroids
for prophylaxis and treatment of nerve function impairment in leprosy: results from the “TRIPOD” trials. Lepr
Rev, 2003; 74: 319–327.
43 Dogra S, Kumaran MS, Narang T et al. Clinical characteristics and outcome in multibacillary leprosy patient
treated with 12 months WHO MDT-MBR: a retrospective analysis of 730 patients from a leprosy clinic at a
tertiary care hospital of Northern India. Lepr Rev, 2013; 84: 65–75.
44 Saunderson PR, Haile-Mariam N. Monitoring steroid use in a field program; possible process indicators. Int J Lepr
Other Mycobact Dis, 1997; 66: 217–223.
Leprosy and tuberculosis concomitant disease 295
